Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TMEM173 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMEM173 Recombinant Protein / Allelic Variants High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View TMEM173 Products |
| Gene Delivery | TMEM173 Lentivirus Full-length ORF for stable cell lines. |
View TMEM173 Products |
| Benchmark Ab | Anti-TMEM173 Benchmark Control Recombinant positive control. |
View TMEM173 Products |
| Validator | TMEM173 siRNA Set For knockdown verification. |
View TMEM173 Products |
| Related Target A | CGAS Upstream synthase in the cGAS-STING pathway. |
View CGAS Products |
| Related Target B | TBK1 Direct downstream kinase activated by STING. |
View TBK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Polymorphic Allele Sensitivity | Major human TMEM173 variants (WT, HAQ, AQ, REF) available with >95% purity |
| Intracellular Target Validation | Lentiviral particles for establishing robust STING-reporter cell lines |
| Lack of Controls | Recombinant positive control antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live TMEM173 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TMEM173 (STING) therapeutics is intensifying, with major players shifting focus from traditional intratumoral injections to systemic small molecule agonists and Immune-Stimulating Antibody Conjugates (ISACs). As first-generation therapies reach the clinic, the next wave of R&D is targeting pan-allelic activation, tumor-targeted delivery to minimize systemic toxicity, and STING antagonists for autoimmune disorders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Mol Agonist | Novartis, GSK, Merck | Solid Tumors | Allele Selectivity Assay (Need High-Purity Variants) |
| ISACs / ADCs | Mersana, Sutro | Targeted Oncology | Internalization & Activation Assay (Need Reporter Cells) |
| Antagonists | IFM Therapeutics | Autoimmune Diseases | Inhibition Validation (Need WT & Mutant Proteins) |